TScan Therapeutics (NASDAQ:TCRX – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02, FiscalAI reports. The business had revenue of $1.05 million for the quarter, compared to the consensus estimate of $1.88 million. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 97.00%.
TScan Therapeutics Stock Performance
NASDAQ TCRX opened at $0.77 on Friday. TScan Therapeutics has a twelve month low of $0.72 and a twelve month high of $2.57. The company has a quick ratio of 6.65, a current ratio of 6.65 and a debt-to-equity ratio of 0.34. The stock has a market cap of $50.45 million, a P/E ratio of -0.85 and a beta of 1.06. The company’s 50-day simple moving average is $0.90 and its 200 day simple moving average is $1.01.
Key TScan Therapeutics News
Here are the key news stories impacting TScan Therapeutics this week:
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating on TScan Therapeutics, maintaining a constructive view of the company despite near-term losses. TScan Therapeutics Earns Buy Rating from HC Wainwright
- Positive Sentiment: TScan reported a second-quarter loss of $0.23 per share, better than the Zacks consensus estimate of a $0.29 loss and the $0.28 loss recorded a year earlier. The smaller-than-expected loss may provide some support. TScan Therapeutics Reports Q2 Loss, Misses Revenue Estimates
- Neutral Sentiment: Brokerage coverage remains divided: HC Wainwright rates the shares Buy, while the broader analyst consensus is Hold. This limits the strength of the bullish signal. TScan Therapeutics Given Consensus Hold Rating
- Negative Sentiment: Second-quarter revenue was $1.05 million, below the approximately $1.88 million consensus estimate. The revenue shortfall highlights continued commercialization and funding risks for the clinical-stage biotechnology company. TScan Therapeutics Reports Q2 Loss, Misses Revenue Estimates
- Negative Sentiment: HC Wainwright reduced its EPS forecasts across fiscal 2026–2030, including lowering expected losses to $0.91 from $0.88 per share for 2026 and to $0.80 from $0.50 for 2029. The revisions suggest a slower path to profitability, even though the firm retained its Buy rating. Analysts Offer Insights on TScan Therapeutics
Institutional Investors Weigh In On TScan Therapeutics
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on TCRX. Benchmark reissued a “buy” rating on shares of TScan Therapeutics in a report on Thursday. Wall Street Zen downgraded TScan Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Friday, July 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Finally, Wedbush reissued an “outperform” rating and set a $5.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $6.00.
Get Our Latest Analysis on TCRX
About TScan Therapeutics
TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.
The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.
Featured Articles
- Five stocks we like better than TScan Therapeutics
- Is Lockheed Martin Gearing Up to Lead Defense Stocks?
- Inside Teledyne’s Bold Bet on the Future of Medical Imaging
- Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
